In this episode, Scott Becker welcomes Molly Gamble, Vice President of Editorial at Becker’s Healthcare, to discuss the latest developments and trends surrounding GLP-1 drugs. Molly shares insights on the issues of counterfeit medications, the emergence of new treatments, and the financial implications for healthcare systems, along with details about an upcoming Becker’s webinar on August 1st focused on GLP-1 questions for health systems.